JP7053473B2 - mRNAの機能状態を変化させてその選択的かつ特異的な認識を可能にする方法 - Google Patents
mRNAの機能状態を変化させてその選択的かつ特異的な認識を可能にする方法 Download PDFInfo
- Publication number
- JP7053473B2 JP7053473B2 JP2018539222A JP2018539222A JP7053473B2 JP 7053473 B2 JP7053473 B2 JP 7053473B2 JP 2018539222 A JP2018539222 A JP 2018539222A JP 2018539222 A JP2018539222 A JP 2018539222A JP 7053473 B2 JP7053473 B2 JP 7053473B2
- Authority
- JP
- Japan
- Prior art keywords
- poly
- sequence
- mrna
- nucleotides
- oligonucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108020004999 messenger RNA Proteins 0.000 title claims description 133
- 238000000034 method Methods 0.000 title claims description 19
- 125000003729 nucleotide group Chemical group 0.000 claims description 88
- 108091034117 Oligonucleotide Proteins 0.000 claims description 85
- 239000002773 nucleotide Substances 0.000 claims description 78
- 108020004707 nucleic acids Proteins 0.000 claims description 62
- 150000007523 nucleic acids Chemical class 0.000 claims description 62
- 102000039446 nucleic acids Human genes 0.000 claims description 62
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 58
- 230000004927 fusion Effects 0.000 claims description 46
- 229920000642 polymer Polymers 0.000 claims description 42
- 125000005647 linker group Chemical group 0.000 claims description 33
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 12
- 108020004414 DNA Proteins 0.000 claims description 9
- -1 (N, N-dimethylamino) ethyl Chemical group 0.000 claims description 7
- 108091027305 Heteroduplex Proteins 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 229920000193 polymethacrylate Polymers 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 claims description 4
- 238000007385 chemical modification Methods 0.000 claims description 4
- 238000003776 cleavage reaction Methods 0.000 claims description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 230000007017 scission Effects 0.000 claims description 4
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 2
- 229920001651 Cyanoacrylate Polymers 0.000 claims description 2
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 229920002873 Polyethylenimine Polymers 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 150000003949 imides Chemical class 0.000 claims description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 2
- 150000002596 lactones Chemical class 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 2
- 229920000765 poly(2-oxazolines) Polymers 0.000 claims description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000005020 polyethylene terephthalate Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 17
- 230000000692 anti-sense effect Effects 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 230000008685 targeting Effects 0.000 description 9
- 239000000074 antisense oligonucleotide Substances 0.000 description 8
- 238000012230 antisense oligonucleotides Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 230000002452 interceptive effect Effects 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 6
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000008878 coupling Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 238000011319 anticancer therapy Methods 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000000771 oncological effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 150000008300 phosphoramidites Chemical class 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 2
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical group O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000004713 phosphodiesters Chemical group 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YVSWPCCVTYEEHG-UHFFFAOYSA-N rhodamine B 5-isothiocyanate Chemical group [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(N=C=S)C=C1C(O)=O YVSWPCCVTYEEHG-UHFFFAOYSA-N 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- GBBJBUGPGFNISJ-YDQXZVTASA-N (4as,7r,8as)-9,9-dimethyltetrahydro-4h-4a,7-methanobenzo[c][1,2]oxazireno[2,3-b]isothiazole 3,3-dioxide Chemical compound C1S(=O)(=O)N2O[C@@]32C[C@@H]2C(C)(C)[C@]13CC2 GBBJBUGPGFNISJ-YDQXZVTASA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- XGDRLCRGKUCBQL-UHFFFAOYSA-N 1h-imidazole-4,5-dicarbonitrile Chemical compound N#CC=1N=CNC=1C#N XGDRLCRGKUCBQL-UHFFFAOYSA-N 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- WNVRHTVLVPXIGY-UHFFFAOYSA-N 2-ethylsulfanyltetrazole Chemical compound CCSN1N=CN=N1 WNVRHTVLVPXIGY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 1
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- FENPYOFIQFTMRH-UHFFFAOYSA-N C(Sn1ncnn1)c1ccccc1 Chemical compound C(Sn1ncnn1)c1ccccc1 FENPYOFIQFTMRH-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
- 108700037122 EWS-FLI fusion Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000005410 Mediastinal Neoplasms Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 108091008121 PML-RARA Proteins 0.000 description 1
- 102000006335 Phosphate-Binding Proteins Human genes 0.000 description 1
- 108010058514 Phosphate-Binding Proteins Proteins 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108700019889 TEL-AML1 fusion Proteins 0.000 description 1
- 238000012338 Therapeutic targeting Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000010560 atom transfer radical polymerization reaction Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000000349 mediastinal cancer Diseases 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical group NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000005987 sulfurization reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3183—Diol linkers, e.g. glycols or propanediols
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/331—Universal or degenerate base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
Description
・配列特異的オリゴヌクレオチドの一次構造に、FITC、RITC、同位体P32などの検出可能な部分を意図的に組み込むことによって、認識された核酸(好ましくはmRNA)の直接検出、可視化、局在化および定量を行う。標識された配列特異的オリゴヌクレオチドの使用は、in situ、in vitro、in vivoおよびex vivoで分析された試料中の認識されたmRNAの定量を可能にする。
・処理された試料中に存在する他の核酸から、認識されたmRNAを精製および選別する。
・配列特異的オリゴヌクレオチドの一次構造に光不安定官能基(photo-labile functional group)を意図的に組み込んで、認識されたmRNAの機能状態の可逆的変化を可能にすることによって、特定の遺伝子の機能解析を行う。
アンチセンス系。標的mRNAの制御された抑制のために現在使用されているアンチセンス系とは異なり(Guoら、2013;Burnett、Rossi、2012;Vaishnawら、2010;Missalidis、2008;Wangら、2003;Clark、2000)、本発明は、一次標的認識の不十分な特異性および選択性(すなわち、アンチセンスオリゴヌクレオチドの無差別性)というそれらの最も重要な欠点を排除する。アンチセンスオリゴヌクレオチドの長さと密接に関連している標準的なアンチセンス系の無差別性は、互いに正確に規定された距離をおいて局在化された標的配列を相補的に認識する2つ(またはそれ以上)のアンチセンスオリゴヌクレオチドの同時干渉によって効果的に解決される。抗癌療法の分野では、特に原因となる融合遺伝子の制御された抑制のために、本発明は、標的mRNA認識のその設計および機構を介して、試験的な(これまでに適用されていない)アンチセンス系を表す。
クレオチドを含む個々のオリゴヌクレオチドとして相互に組み合わされ得る。核酸塩基および糖リン酸骨格の両方を化学的に修飾してもよい。
A:糖部分の修飾、B:リン酸結合の修飾、C:糖リン酸骨格の修飾。
・ヌクレオチドは、A、I、U、T、C、Gまたはそれらの誘導体であってよく、
・オリゴヌクレオチドは、ヌクレオチドまたはそれらの誘導体の任意の相互の組合せを含んでもよい。
配列特異的オリゴヌクレオチド。配列特異的オリゴヌクレオチドの化学合成は、ホスホロアミダイト法を用いた固体支持体を用いて、すなわち保護された2’-デオキシヌクレオシド(dA、dC、dG、dT)、リボヌクレオシド(A、C、G、U)または他の化学的に修飾されたヌクレオシド由来の個々のモノマーの連続オリゴマー化を介して行われるが、それらの特定の選択および配列の順序は最終用途に応じて決まる。合成サイクルは、標的核酸(好ましくはmRNA)に相補的な配列に対応する順序で、個々のヌクレオシドの成長オリゴマーへの段階的コンジュゲーションを含む。完了すると、配列特異的オリゴヌクレオチドが固体支持体から溶液に放出され、ポリマー連結部分とのコンジュゲーションのために調製される。
合成サイクル。サイズ特異的オリゴヌクレオチドの合成は、所望の配列が得られるまで、合成サイクルあたり1個のヌクレオチドが成長オリゴマーに加えられると、3’から5’方向に段階的に進行する(Greco、Tor、2007)。
不活性溶媒(ジクロロメタンまたはトルエン)中、酸、例えば2%トリクロロ酢酸または3%ジクロロ酢酸の溶液によって、ジメトキシトリチル(DMT)保護基を除去する。
酸性アゾール触媒、すなわち1H-テトラゾール、2-エチルチオテトラゾール、2-ベンジルチオテトラゾール、4,5-ジシアノイミダゾールまたは他の類似した化合物の0.2~0.7M溶液によって、アセトニトリル中のヌクレオシドホスホルアミダイトの0.02~0.2M溶液を活性化させる(Wei、2013)。次いで、支持体結合オリゴヌクレオチドに対して1.5~2.0倍過剰の活性化ホスホルアミダイトと、出発固体支持体(第1のカップリング)または支持体結合オリゴヌクレオチド前駆体(カップリング後)とを反応させる。5’-ヒドロキシ基は、入ってくるヌクレオシドホスホルアミダイトの活性化ホスホルアミダイト部分と反応して亜リン酸トリエステル結合を形成する。カップリング反応の完了時に、未結合の試薬および副生成物を洗浄によって除去する。
続いて、弱塩基(ピリジン、ルチジンまたはコリジン)の存在下でヨウ素および水を用いて、新たに形成された三配位亜リン酸トリエステル結合を四配位リン酸トリエステルに酸化させる。酸化は、tert-ブチルヒドロペルオキシド(Alulら、1991)を用いて、または最終的に(1S)-(+)-(10-カンファースルホニル)-オキサジリジン(Manoharanら、2000)を用いて、無水条件下で行ってもよい。
無水酢酸と1-メチルイミダゾールとの混合物を用いて、固体支持体結合材料を処理する。
固体支持体からのオリゴヌクレオチドの切断と、脱保護とは、濃水酸化アンモニウムを用いて行う。
一般的なRNAおよびDNAオリゴヌクレオチドと同様に、ホスホジエステル骨格中の酸素原子の1つが硫黄原子に置換されている修飾オリゴヌクレオチドを合成する(詳細については、合成サイクルの項を参照のこと)。相違点は、酸化工程を硫化に置き換えることにある。
Obikaら(1997)およびKoshkinら(1998)に従って、リボースが2’-Oおよび4’-C原子間の共有結合架橋によって修飾されている修飾オリゴヌクレオチドを合成する。
Nielsenら(1991)に従って、ペプチド様結合を介して相互に連結されたN-(2-アミノエチル)-グリシン単位を繰り返すことによって糖リン酸骨格が形成されている修飾オリゴヌクレオチドを合成する。
SummertonおよびWeller(1991、1993b、1997)に従って、核酸塩基がモルホリン環に連結され、ホスホロジアミデート結合を介して相互接続されている修飾オリゴヌクレオチドを合成する。
Uedaら(1971)およびCookら(1995、1999)に従って、ホスホジエステル結合を介して相互接続されたグリコール部分を繰り返すことによって糖リン酸骨格が構成されている修飾オリゴヌクレオチドを合成する。
ChaputおよびSzostak(2003)に従って、糖リン酸骨格がリボースの代わりにトレオースによって構成されている修飾オリゴヌクレオチドを合成する。
融合PML-RARA mRNA 融合BCM-IL2 mRNA
融合TEL-AML1 mRNA 融合CEV14-PDGFRB mRNA
融合TCR-RBTN2 mRNA 融合RBM15-MKL mRNA
融合TMPRSS2-ETS mRNA 融合ETV6-NTRK3 mRNA
融合NPM-ALK mRNA 融合TFE3-PRCC mRNA
融合PLZF-RARA mRNA 融合TFE3-ASPSCR1 mRNA
融合MLL-AF9 mRNA 融合PAX8-PPARG mRNA
融合DEK-CAN mRNA 融合TET1-TP53 mRNA
融合FUS-ERG mRNA 融合TFEB-ALPHA mRNA
融合AML1-MTG mRNA 融合TFE3-PSF mRNA
融合AML1-EAP mRNA 融合CHOP-EWS mRNA
融合NUP98-PMX1 mRNA 融合PAX3-FKHR mRNA
融合MLL-AFP1 mRNA 融合JAZF1-JJAZ1 mRNA
融合EA2-HLF mRNA 融合FUS-CREB312 mRNA
融合MOZ-P300 mRNA 融合TPM3-ALK mRNA
融合TEL-PDGFRB mRNA 融合CLTC-ALK mRNA
融合MLL-AFX1 mRNA 融合RPN1-EVI1 mRNA
融合E2A-PBX1 mRNA 融合EWS-FLI1 mRNA
融合MLL-AF6 mRNA 融合AML1-EVI-1 mRNA
融合NUP98-HOXA9 mRNA 融合ETV6-MN1 mRNA
融合MLL-AF4 mRNA 融合MLL-ENL mRNA
融合NUP98-RAP1GDS1 mRNA 融合CALM-AF10 mRNA
融合FUS-CHOP mRNA 融合PAX7-FKHR mRNA
融合SYT-SSX mRNA 融合EWS-CHN mRNA
融合TCF12-TEC mRNA 融合EWS-WT1 mRNA
融合ASPL-TFE3 mRNA 融合COL1A1-PDGFB mRNA
融合TPM4-ALK mRNA
Claims (11)
- 標的核酸を構築物と接触させてヘテロ二本鎖を形成する方法であって、
標的核酸が、標的mRNAであり、
該構築物は、1つの連結部分を介して相互接続された2つの配列特異的一本鎖オリゴヌクレオチドを含み、
該配列特異的な一本鎖オリゴヌクレオチドの各々は、該標的核酸の標的配列に結合してヘテロ二本鎖を形成し、
該配列特異的一本鎖オリゴヌクレオチドが、10乃至25ヌクレオチドを含み、
該構築物は該標的核酸に特異的に結合し、
該連結部分は、該配列特異的一本鎖オリゴヌクレオチドが該標的核酸の標的配列に結合してヘテロ二本鎖を形成することを可能にする長さを含み、そして
該連結部分は、以下から選択される
a)無塩基の糖リン酸骨格、無塩基の化学的に修飾された糖リン酸骨格、またはそれらの組み合わせ;
b)ポリペプチド;
c)多糖;
d)炭素原子数2乃至40の飽和または不飽和炭化水素;
e)ポリ(メタ)アクリレート、変性ポリ(メタ)アクリレート、ポリ(ビニルアルコール)、ポリ(ビニルピロリドン)、ポリ(エチレングリコール)、ポリ(アクリルアミド)、ポリ(オキサゾリン)、ポリ(エチレンイミン)、ポリ(アルキレンオキシド)、ラクトンベースのポリマー、ポリ(アクリル酸)、ポリ(ラクチド酸)、ポリ(グリコール酸)、ポリ(プロピレン)、ポリ(スチレン)、ポリ(オレフィン)、ポリ(アミド)、ポリ(シアノアクリレート)、ポリ(イミド)、ポリ(エチレンテレフタレート)、ポリ(テトラメチレングリコール)、ポリ(ウレタン)またはそれらの組み合わせを含む非ヌクレオチドポリマー;または
f)a)乃至e)のいずれか1つの組み合わせ、
を含む、方法。 - 前記標的mRNAが融合mRNAである、請求項1に記載の方法。
- 前記標的配列が、融合切断点部位から100ヌクレオチド以下に局在化する、請求項1に記載の方法。
- 前記構築物が、連結部分を介して相互接続される少なくとも3つの配列特異的一本鎖オリゴヌクレオチドを含み、そして該配列特異的一本鎖オリゴヌクレオチドのそれぞれが該標的核酸の標的配列に結合する、請求項1に記載の方法。
- 前記連結部分の長さが、5乃至1000オングストロームの間の範囲である、請求項1に記載の方法。
- 前記連結部分が、一つの配列特異的一本鎖オリゴヌクレオチドの5’末端および別の配列特異的一本鎖オリゴヌクレオチドの3’末端に結合している、請求項1に記載の方法。
- 前記連結部分がポリマー連結部分である、請求項1に記載の方法。
- 前記変性ポリ(メタ)アクリレートが、ポリ(エチレンオキシ)、2(N,N-ジメチルアミノ)エチル(メタ)アクリレート、またはそれらの組み合わせを含む、請求項1に記載の方法。
- 前記それぞれの配列特異的一本鎖オリゴヌクレオチドの長さが、少なくとも3ヌクレオチドであり、且つ、該配列特異的一本鎖オリゴヌクレオチドがDNA、RNA、ヌクレオチド誘導体、ヌクレオチド類似体、又は二種又はそれ以上のDNA、RNA、ヌクレオチド誘導体、もしくはヌクレオチド類似体の組み合わせを含む、請求項1に記載の方法。
- 前記DNA、RNA、ヌクレオチド誘導体、ヌクレオチド類似体、又は二種又はそれ以上のDNA、RNA、ヌクレオチド誘導体、もしくはヌクレオチド類似体の組み合わせが、特異的な化学修飾を有するオリゴヌクレオチドのブロックとして、または異なる修飾ヌクレオチドからなる個々のオリゴヌクレオチドとして、相互に組み合わされる、請求項9に記載の方法。
- 前記配列特異的一本鎖オリゴヌクレオチドが、DNA、RNA、2’-O-(2-メトキシエチル)-RNA、2’-O-メチル-RNA、2’-フルオロ-RNA、LNA、PNA、モルホリノ、INA、FANA、ANA、UNA、HNA、またはそれらの組み合わせを含む、請求項1に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022059685A JP2022097486A (ja) | 2015-10-15 | 2022-03-31 | mRNAの機能状態を変化させてその選択的かつ特異的な認識を可能にする方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SK50065-2015A SK500652015A3 (sk) | 2015-10-15 | 2015-10-15 | Spôsob úpravy funkčného stavu ľubovoľnej mRNA umožňujúci jej selektívne a špecifické rozpoznanie |
SKPP50065-2015 | 2015-10-15 | ||
PCT/SK2016/060002 WO2017065696A2 (en) | 2015-10-15 | 2016-10-12 | A method for altering the functional state of mrna allowing its selective and specific recognition |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022059685A Division JP2022097486A (ja) | 2015-10-15 | 2022-03-31 | mRNAの機能状態を変化させてその選択的かつ特異的な認識を可能にする方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018534945A JP2018534945A (ja) | 2018-11-29 |
JP7053473B2 true JP7053473B2 (ja) | 2022-04-12 |
Family
ID=58267152
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018539222A Active JP7053473B2 (ja) | 2015-10-15 | 2016-10-12 | mRNAの機能状態を変化させてその選択的かつ特異的な認識を可能にする方法 |
JP2022059685A Pending JP2022097486A (ja) | 2015-10-15 | 2022-03-31 | mRNAの機能状態を変化させてその選択的かつ特異的な認識を可能にする方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022059685A Pending JP2022097486A (ja) | 2015-10-15 | 2022-03-31 | mRNAの機能状態を変化させてその選択的かつ特異的な認識を可能にする方法 |
Country Status (18)
Country | Link |
---|---|
US (1) | US11371038B2 (ja) |
EP (1) | EP3362098B1 (ja) |
JP (2) | JP7053473B2 (ja) |
KR (1) | KR102307184B1 (ja) |
AU (1) | AU2016336851B2 (ja) |
CA (1) | CA3001994A1 (ja) |
DK (1) | DK3362098T3 (ja) |
ES (1) | ES2920887T3 (ja) |
HR (1) | HRP20220968T1 (ja) |
HU (1) | HUE058829T2 (ja) |
LT (1) | LT3362098T (ja) |
PL (1) | PL3362098T3 (ja) |
PT (1) | PT3362098T (ja) |
RS (1) | RS63354B1 (ja) |
RU (1) | RU2724485C2 (ja) |
SI (1) | SI3362098T1 (ja) |
SK (1) | SK500652015A3 (ja) |
WO (1) | WO2017065696A2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11419947B2 (en) | 2017-10-30 | 2022-08-23 | Massachusetts Institute Of Technology | Layer-by-layer nanoparticles for cytokine therapy in cancer treatment |
US12018315B2 (en) * | 2019-05-30 | 2024-06-25 | Massachusetts Institute Of Technology | Peptide nucleic acid functionalized hydrogel microneedles for sampling and detection of interstitial fluid nucleic acids |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003116559A (ja) | 2001-10-11 | 2003-04-22 | Keio Gijuku | 新規マキシザイム |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
JPH06508622A (ja) * | 1991-06-18 | 1994-09-29 | テンプル ユニバーシティ−オブ ザ コモンウェルス システム オブ ハイヤーエデュケーション | bcr−ab1アンチセンスオリゴヌクレオチドによる白血球増殖の選択的抑制 |
CA2092571A1 (en) | 1991-08-01 | 1993-02-02 | David S. Snyder | Ribozyme inhibition of bcr-abl gene expression |
US6080851A (en) * | 1992-12-04 | 2000-06-27 | American Home Products Corporation | Ribozymes with linked anchor sequences |
US5556752A (en) * | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US5747248A (en) | 1994-12-05 | 1998-05-05 | Chiron Corporation | Discontinuous probe design using hybritope mapping |
US6458940B2 (en) * | 1995-06-06 | 2002-10-01 | Hybridon, Inc. | HPV-specific oligonucleotides |
AU755913B2 (en) * | 1997-06-18 | 2003-01-02 | Masad Damha | Nucleic acid biosensor diagnostics |
FR2781802B1 (fr) * | 1998-07-31 | 2001-05-11 | Bio Merieux | Derives satures ou insatures de l'abietane, conjugues derives et utilisations dans une composition diagnostique, un reactif et un dispositif |
WO2001073002A2 (en) * | 2000-03-27 | 2001-10-04 | University Of Delaware | Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
DE10202419A1 (de) * | 2002-01-22 | 2003-08-07 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens |
US7851453B2 (en) | 2003-01-16 | 2010-12-14 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
KR20060015505A (ko) * | 2003-04-13 | 2006-02-17 | 엔존 파마슈티컬즈, 인코포레이티드 | 올리고뉴클레오타이드 전구약물 |
US20050256072A1 (en) | 2004-02-09 | 2005-11-17 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
US20060105975A1 (en) | 2004-04-19 | 2006-05-18 | Shannon Pendergrast | Aptamer-mediated intracellular delivery of therapeutic oligonucleotides |
MX2010001785A (es) | 2007-08-15 | 2010-03-10 | Idera Pharmaceuticals Inc | Moduladores de receptores tipo larga distancia. |
HUE026020T2 (en) | 2009-08-27 | 2016-05-30 | Idera Pharmaceuticals Inc | Preparation for inhibiting gene expression and its uses |
US20130079505A1 (en) | 2010-03-24 | 2013-03-28 | Mirrx Therapeutics A/S | Bivalent antisense oligonucleotides |
KR101590586B1 (ko) * | 2011-05-30 | 2016-02-01 | 성균관대학교산학협력단 | 표적 유전자 발현 억제 및 면역 반응을 동시에 유발하는 이중가닥의 긴 간섭 rna |
ES2578370T3 (es) * | 2011-07-01 | 2016-07-26 | HTG Molecular Diagnostics, Inc | Métodos para detectar fusiones génicas |
US10605810B2 (en) * | 2013-12-30 | 2020-03-31 | University-Industry Cooperation Group Of Kyung Hee University | Pincers comprising antibody and aptamer conjugated via a linker which binds to the same target material and use thereof |
-
2015
- 2015-10-15 SK SK50065-2015A patent/SK500652015A3/sk unknown
-
2016
- 2016-10-12 KR KR1020187010701A patent/KR102307184B1/ko active IP Right Grant
- 2016-10-12 CA CA3001994A patent/CA3001994A1/en active Pending
- 2016-10-12 ES ES16845348T patent/ES2920887T3/es active Active
- 2016-10-12 LT LTEPPCT/SK2016/060002T patent/LT3362098T/lt unknown
- 2016-10-12 AU AU2016336851A patent/AU2016336851B2/en active Active
- 2016-10-12 SI SI201631562T patent/SI3362098T1/sl unknown
- 2016-10-12 EP EP16845348.8A patent/EP3362098B1/en active Active
- 2016-10-12 PT PT168453488T patent/PT3362098T/pt unknown
- 2016-10-12 HU HUE16845348A patent/HUE058829T2/hu unknown
- 2016-10-12 HR HRP20220968TT patent/HRP20220968T1/hr unknown
- 2016-10-12 WO PCT/SK2016/060002 patent/WO2017065696A2/en active Application Filing
- 2016-10-12 PL PL16845348.8T patent/PL3362098T3/pl unknown
- 2016-10-12 US US15/768,586 patent/US11371038B2/en active Active
- 2016-10-12 RU RU2018117650A patent/RU2724485C2/ru active
- 2016-10-12 RS RS20220639A patent/RS63354B1/sr unknown
- 2016-10-12 DK DK16845348.8T patent/DK3362098T3/da active
- 2016-10-12 JP JP2018539222A patent/JP7053473B2/ja active Active
-
2022
- 2022-03-31 JP JP2022059685A patent/JP2022097486A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003116559A (ja) | 2001-10-11 | 2003-04-22 | Keio Gijuku | 新規マキシザイム |
Also Published As
Publication number | Publication date |
---|---|
JP2018534945A (ja) | 2018-11-29 |
KR20180084748A (ko) | 2018-07-25 |
NZ742493A (en) | 2021-09-24 |
AU2016336851B2 (en) | 2020-06-18 |
KR102307184B1 (ko) | 2021-10-01 |
ES2920887T3 (es) | 2022-08-11 |
LT3362098T (lt) | 2022-06-27 |
RS63354B1 (sr) | 2022-07-29 |
CA3001994A1 (en) | 2017-04-20 |
US11371038B2 (en) | 2022-06-28 |
JP2022097486A (ja) | 2022-06-30 |
PL3362098T3 (pl) | 2022-07-18 |
WO2017065696A2 (en) | 2017-04-20 |
US20180291366A1 (en) | 2018-10-11 |
PT3362098T (pt) | 2022-06-06 |
EP3362098B1 (en) | 2022-05-04 |
SI3362098T1 (sl) | 2022-08-31 |
RU2018117650A (ru) | 2019-11-15 |
RU2724485C2 (ru) | 2020-06-23 |
HUE058829T2 (hu) | 2022-09-28 |
DK3362098T3 (da) | 2022-07-18 |
RU2018117650A3 (ja) | 2019-11-15 |
WO2017065696A3 (en) | 2017-07-06 |
EP3362098A2 (en) | 2018-08-22 |
HRP20220968T1 (hr) | 2022-10-28 |
SK500652015A3 (sk) | 2017-05-03 |
AU2016336851A1 (en) | 2018-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022097486A (ja) | mRNAの機能状態を変化させてその選択的かつ特異的な認識を可能にする方法 | |
Kaur et al. | Perspectives on chemistry and therapeutic applications of Locked Nucleic Acid (LNA) | |
Eaton et al. | Post-SELEX combinatorial optimization of aptamers | |
JP4383720B2 (ja) | オリゴヌクレオチドn3’→p5’ホスホルアミデート:合成および化合物;ハイブリダイゼーションおよびヌクレアーゼ耐性特性 | |
Lonnberg | Solid-phase synthesis of oligonucleotide conjugates useful for delivery and targeting of potential nucleic acid therapeutics | |
Borgatti et al. | Transcription factor decoy molecules based on a peptide nucleic acid (PNA)-DNA chimera mimicking Sp1 binding sites | |
JP2008501694A5 (ja) | ||
JP2005517436A5 (ja) | ||
WO2011129494A1 (en) | Nucleolin specific aptamer and use thereof | |
IL185569A (en) | Cyclic acid and analogues of nucleotide nucleotides and oligonucleotides | |
JP2005517438A5 (ja) | ||
JPH06128284A (ja) | 合成触媒オリゴヌクレオチド構造、核酸の目標配列の切断方法、抗ウイルス治療用薬剤ならびにその製造方法、診断試薬及びその製造方法 | |
Kwiatkowska et al. | siRNAs modified with boron cluster and their physicochemical and biological characterization | |
Kundu et al. | Synthesis of phosphorodiamidate morpholino oligonucleotides using trityl and fmoc chemistry in an automated oligo synthesizer | |
JP2023534951A (ja) | 組織特異的送達のためのコンジュゲートされたオリゴヌクレオチド | |
CN113164507A (zh) | 由多个寡核苷酸构成的通过与靶标的互补相互作用调控基因表达的多靶向核酸构建体 | |
Morihiro et al. | anti–syn unnatural base pair enables alphabet-expanded dna self-assembly | |
Seth et al. | The medicinal chemistry of RNase H-activating antisense oligonucleotides | |
Avino et al. | Branched RNA: a new architecture for RNA interference | |
Yang | Solid‐Phase Synthesis of Oligodeoxynucleotide Analogs Containing Phosphorodithioate Linkages | |
Donovan et al. | Aptamer–drug conjugation for targeted tumor cell therapy | |
EP1730158A2 (en) | Methods and compositions for in vitro and in vivo use of parallel stranded hairpins and triplex structures as nucleic acid ligands | |
NZ742493B2 (en) | A method for altering the functional state of mrna allowing its selective and specific recognition | |
JP2022120380A (ja) | miRNA133-b誘導体及びその利用 | |
Laikhter et al. | The Chemical Synthesis of Oligonucleotides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180925 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20190315 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20190315 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190315 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190725 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200625 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200701 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200923 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201224 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210602 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210804 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211025 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211201 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220302 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220331 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7053473 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |